BlueCross BlueShield of Florida Continues Trend, Retires Negative FeNO Policy


BlueCross BlueShield of Florida Continues Trend, Retires Negative FeNO Policy

SOLNA, Sweden - 16 March, 2012 - Aerocrine AB (NASDAQ OMX NORDIC: AERO)
announces that BlueCross BlueShield (BC BS) of Florida1 has retired/archived
their negative medical policy for FeNO testing. The change is effective March
15, 2012.

On March 15, 2012 BC BS of Florida retired their negative coverage policy
regarding Fractional exhaled Nitric Oxide (FeNO). BC BS of Florida is one of the
largest insurance companies in the state and provides insurance coverage to
approximately 31% of all privately insured or about 2.6 million lives. With this
and other recent private payer coverage changes, FeNO coverage in the state of
Florida is now estimated to be over 50%.

Aerocrine estimates that this coverage decision, published only yesterday,
together with the recent announcement of UnitedHealthcare’s policy retirement
means that over 35% of the privately insured lives in the U.S. are now eligible
for reimbursement for Aerocrine’s test, an increase from around 15% at the end
of 2011. 2

“We are very pleased that the number of eligible lives continues to increase and
with this policy decision, Aerocrine has confirmed BlueCross BlueShield coverage
in 21 states and the District of Columbia.,” said Scott Myers, CEO, Aerocrine
AB. 

Asthma is one of this world’s most common and costly diseases, affecting 7-10%
of the population and costing over $50B annually in the US alone. The disease
has no cure and proper diagnosis and management of the disease are key to
physicians effectively treating patients.
Aeorcrine’s NIOX MINO monitor and tests are sold to physicians to help them
diagnose airway inflammation, the underlying cause of the majority of asthmatic
conditions. FeNO testing can also help physicians identify patients who will be
responsive to treatment with anti-inflammatory medications such as inhaled
corticosteroids (ICS), and alert them to patients who are not adhering to their
treatments.

"Nitric oxide measurement enables physicians the ability to better diagnose and
manage patients with airway inflammation. We will be better able to identify
patients who will respond to inhaled corticosteroids and even determine in whom
we may be able to decrease the doses of asthma controller medications," said
Sunil Joshi, MD FACAAI and President of the Florida Allergy Asthma Immunology
Society.

“Since the release of the American Thoracic Guideline on FeNO, there has been
significant improvement in reimbursement. Taking into account that the
cornerstone of asthma management is control of airway inflammation, testing with
FeNO should be mandatory for anyone receiving an ICS therapy – this benefits the
patient as well as decrease the cost burden of asthma”, said Kathy Hodgdon, US
Director of Sales and Marketing, Aerocrine.

1)     http://mcgs.bcbsfl.com/

2)     AIS 2011 Directory of Health Plans, Health Plans USA 2011, www.CMS.gov

For more information, contact:

Scott Myers, President & CEO, Aerocrine AB, Phone: +46 768 788 379

Kathy Hodgdon, Director of sales & marketing, Aerocrine Inc., telephone +1 (314)
566 8546

Chip Neff, President, Aerocrine Inc., telephone +1 (919) 696 4267

Anhänge

GlobeNewswire